Adipogen/Kdo2-Lipid A (ready-to-use)/AG-CU1-0001-M001/1 mg
商品编号：
AG-CU1-0001-M001
品牌：
Adipogen Inc
市场价：
¥3000.00
美元价：
1800.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| ProductDetails | |
|---|---|
| Synonyms | (3-Deoxy-D-manno-octulosonicacid)2-LipidA |
| ProductType | Chemical |
| Properties | |
| Formula | C110H198N2Na4O39P2 |
| MW | 2326.7 |
| CAS | 123621-04-5(freebase) |
| Source/HostChemicals | IsolatedandpurifiedfromE.coliK12heptose-deficientstrainWBB06(Remutant). |
| PurityChemicals | AbsenceofdetectableproteinorDNAcontaminantswithagoNISTicTLRactivity. |
| Appearance | Clear,colorlesssolution. |
| Formulation | Liquid.Sterile,ready-to-usesolutioninpyrogen-freedoubledistilledwater. |
| Concentration | 0.5mg/ml.Vialcontains2ml. |
| OtherProductData | Strongactivator(<10ng/ml)oftoll-likereceptor4(TLR4).DoesnotactivateTLR2orotherTLRsasdeterminedwithsplenocytesandmacrophagesfromTLR4deficientmice.Nofurtherre-extractionrequired. IsolatedandpurifiedfromE.coliK12heptose-deficientstrainWBB06(Remutant)[1]byamodificationofthePCPextractionmethod[2,3],convertedtotheuniformsodiumsaltform[4]anddissolvedinsterilepyrogen-freedoubledistilledwater. Lit:[1]DeletionoftheheptosyltransferasegenesrfaCandrfaFinEscherichiacoliK-12resultsinaRe-typelipopolysaccharidewithahighdegreeof2-aminoethanolphosphatesubstitution:W.Brabetz,etal.;Eur.J.Biochem.247,716(1997)/[2]AnewmethodfortheextractionofRlipopolysaccharides:C.Galanos,etal.;Eur.J.Biochem.9,245(1969)/[3]IsolationandpurificationofR-formlipopolysaccharides:C.Galanos&O.Luderitz;Meth.CarbohydrateChem.9,11(1993)/[4]Electrodialysisoflipopolysaccharidesandtheirconversiontouniformsaltforms:C.Galanos&O.Lüderitz;Eur.J.Biochem.54,603(1975) |
| InChiKey | HBSUHPVFGADBOQ-USMMBHRMSA-N |
| ShippingandHandling | |
| Shipping | AMBIENT |
| ShortTermStorage | +4°C |
| LongTermStorage | +4°C |
| HandlingAdvice | Keepsterile.Donotingest.Wearglovesandmask.Avoidcontactthroughallmodesofexposure.Avoidinhalationandpreventfromenteringthebloodstream.Usemustberestrictedtoqualifiedpersonnel. |
| Use/StABIlity | Stableforatleast2yearsafterreceiptwhenstoredat+4°C. |
| Documents | |
| MSDS |  DownloadPDF |
| ProductSpecificationSheet | |
| Datasheet | DownloadPDF |
- DefinedsubstructureoftheRemutantoflipopolysaccharide(LPS)[1].
- EndotoxinactivityequaltoReLPS[1].
- Strongactivator(<10ng/ml)ofmacrophagesviatoll-likereceptor4(TLR4)[1,2,3,4,9].
- DoesnotactivateTLR2[5]orotherTLRsasdeterminedwithsplenocytesandmacrophagesfromTLR4deficientmicebyIL-6ELISA[1,4].
- Facilitatesthestructuralanalysisofitscomplexeswithsignalingreceptors,suchasTLR4/MD2[1,2]andCD14[7].
- Kdo2-LipidAwasusedinarecentanimalatherosclerosismodel[6].
- Inducessphingolipidbiosynthesis,whichisessentialforinductionofautophagy[8].
ProductReferences
- Kdo2-LipidAofEscherichiacoli,adefinedendotoxinthatactivatesmacrophagesviaTLR-4:C.R.Raetz,etal.;J.LipidRes.47,1097(2006)
- Aggregationbehaviorofanultra-purelipopolysaccharidethatstimulatesTLR-4receptors:H.Sasaki&S.H.White;Biophys.J.95,986(2008)
- TLR-4mediatedgroupIVAphospholipaseA(2)activationisphosphatidicacidphosphohydrolase1andproteinkinaseCdependent:A.Grkovich,etal.;BBA1791,975(2009)
- SubcellularorganellelipidomicsinTLR4-activatedmacrophages:A.Y.Andreyev,etal.;J.LipidRes.51,2785(2010)
- SpinalglialTLR4-mediatednociceptionandproductionofprostaglandinEandTNF:O.Saito,etal.;Br.J.Pharmacol.160,1754(2010)
- Lowdosesoflipopolysaccharideandminimallyoxidizedlow-densitylipoproteincooperativelyactivatemacrophagesvianuclearfactorkappabandactivatorprotein-1-possIBLemechanismforaccelerationofatherosclerosisbysubclinicalendotoxemia:P.Wiesner,etal.;Circ.Res.107,56(2010)
- NMRspectralmappingofLipidAmolecularpatternsaffectedbyinteractionwiththeinnateimmunereceptorCD14:S.Albright,etal.;BBRC378,721(2009)
- Kdo2-lipidA,aTLR4-specificagonist,inducesdenovosphingolipidbiosynthesisinRAW264.7macrophages,whichisessentialforinductionofautophagy:K.Sims,etal.;J.Biol.Chem.285,28568(2010)
- ATF3playsakeyroleinKdo2-lipidA-inducedTLR4-dependentgeneexpressionviaNF-?Bactivation:E.Y.Kim,etal.;PLoSOne5,e14181(2010)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
